Search - tctmd.com

Displaying 361 - 380 of 963

Sort: Relevancy | Date

News Conference News TCT 2017

No Late Quality of Life Trade-offs With PCI in Left Main Disease: EXCEL-QOL Substudy

Michael O'Riordan

October 30, 2017

Presentation TCT 2017

Drug Eluting Scaffold With an Absorbable Platform for Primary Lower Extremity Arterial Revascularization DESappear Study Initial Results

Presenter: Tony Das, Thomas Zeller

October 30, 2017

News Conference News TCT 2017

CULPRIT-SHOCK Disputes Benefit of Immediate Multivessel PCI in Patients With Cardiogenic Shock

Todd Neale

October 30, 2017

News Conference News TCT 2017

Help for Clinicians Whose Patients Need to Switch P2Y12 Inhibitors

Todd Neale

October 30, 2017

Presentation TCT 2017

Predicting The Future: Will the Ongoing DES 3-Month DAPT Studies With Synergy and Xience Change How We Treat High Risk Bleeding Patients?

Presenter: C. Michael Gibson, Stephan Windecker

October 30, 2017

Presentation TCT 2017

Predicting The Future: Will the ABSORB III/IV Ten-Year Results Change How We Currently View Bioresorbable Vascular Scaffolds?

Presenter: C. Michael Gibson, Stephan Windecker, Stephan Achenbach

October 30, 2017

News Opinion Off Script TCT 2017

Off Script: Welcome to TCT 2017 in the Mile High City

Kwan S. Lee

October 29, 2017

Presentation TCT 2017

What Is the Future of Bioabsorbable Scaffolds?

Presenter: Anibal A. Damonte, Alejandro O. Palacios, Patrick W. Serruys

October 29, 2017

Presentation TCT 2017

Next Generation BRS Platforms

Presenter: Gary S. Mintz, Seung-Jung Park, Alan C. Yeung

October 29, 2017

Presentation TCT 2017

Bioresorbable Scaffolds and Outcomes 2017

Presenter: Joseph P. Carrozza Jr, Jose M. Wiley, Jochen Wöhrle

October 29, 2017

Presentation TCT 2017

BRS Randomized Trials: What Was Wrong the Lesions, the Scaffold, or the Technique?

Presenter: Gary S. Mintz, Seung-Jung Park

October 29, 2017

Presentation TCT 2017

Lessons from the ABSORB Clinical Program for the Future

Presenter: Gary S. Mintz, Seung-Jung Park, Patrick W. Serruys

October 29, 2017

Presentation TCT 2017

Drug-Eluting Stent Thrombosis and Restenosis: Mechanisms, Frequency, and Treatment

Presenter: Joseph P. Carrozza Jr, Jose M. Wiley, Binita Shah

October 29, 2017

Presentation TCT 2017

Drug-Eluting Stent Platforms and Outcomes 2017

Presenter: Joseph P. Carrozza Jr, Jose M. Wiley, Gennaro Sardella

October 29, 2017

Presentation TCT 2017

Bioresorbable Scaffolds Are Here to Stay!

Presenter: Antonio Colombo, Stephen G. Ellis, Ron Waksman

October 29, 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2017

Shelley Wood

October 29, 2017

Presentation TCT 2017

Interventional Pathobiology: A Practical Anatomical Description for SHD Procedures

Presenter: Alexandre Abizaid, Oscar A. Mendiz, Juan F. Granada

October 29, 2017

Presentation TCT 2017

Case Presentation: DCB in a De Novo Lesion

Presenter: Roxana Mehran, Bo Xu, Jun Jiang

October 29, 2017

Presentation TCT 2017

Current Practice and Perspectives on DCB in China

Presenter: Roxana Mehran, Bo Xu, YunDai Chen

October 29, 2017

Presentation TCT 2017

Flash Debate #3: Should BVS Scaffolds Be Used Today? No - The Evidence Says So!

Presenter: Jun-Jack Cheng, Kenneth Chin, Jack Wei Chieh Tan

October 29, 2017

Advertisement

No Late Quality of Life Trade-offs With PCI in Left Main Disease: EXCEL-QOL Substudy

Drug Eluting Scaffold With an Absorbable Platform for Primary Lower Extremity Arterial Revascularization DESappear Study Initial Results

CULPRIT-SHOCK Disputes Benefit of Immediate Multivessel PCI in Patients With Cardiogenic Shock

Help for Clinicians Whose Patients Need to Switch P2Y12 Inhibitors

Predicting The Future: Will the Ongoing DES 3-Month DAPT Studies With Synergy and Xience Change How We Treat High Risk Bleeding Patients?

Predicting The Future: Will the ABSORB III/IV Ten-Year Results Change How We Currently View Bioresorbable Vascular Scaffolds?

Off Script: Welcome to TCT 2017 in the Mile High City

What Is the Future of Bioabsorbable Scaffolds?

Next Generation BRS Platforms

Bioresorbable Scaffolds and Outcomes 2017

BRS Randomized Trials: What Was Wrong the Lesions, the Scaffold, or the Technique?

Lessons from the ABSORB Clinical Program for the Future

Drug-Eluting Stent Thrombosis and Restenosis: Mechanisms, Frequency, and Treatment

Drug-Eluting Stent Platforms and Outcomes 2017

Bioresorbable Scaffolds Are Here to Stay!

TCTMD’s Top 10 Most Popular Stories for October 2017

Interventional Pathobiology: A Practical Anatomical Description for SHD Procedures

Case Presentation: DCB in a De Novo Lesion

Current Practice and Perspectives on DCB in China

Flash Debate #3: Should BVS Scaffolds Be Used Today? No - The Evidence Says So!

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content